目的:了解肿瘤疫苗临床研究的最新进展,为肿瘤疫苗的研发提供参考.方法:依据国内、外研究文献和临床试验注册平台及相关专利等信息,对已上市和进入Ⅲ期临床试验的肿瘤疫苗的临床研究最新进展进行综述.结果与结论:目前已上市或进入Ⅲ期临床试验的肿瘤疫苗以树突细胞疫苗、抗原佐剂疫苗和肿瘤细胞疫苗为主,多用于宫颈癌、黑色素瘤、肺癌、乳腺癌、前列腺癌等的预防和治疗.%OBJECTIVE: To clarify the important significance of cost-effectiveness threshold for pharmacoeconomics and pharma-coeconomic evaluation from the perspective of net benefit. METHODS: Every kind of net benefit was introduced, and the internal relationship of net benefits and cost-effectiveness threshold was demonstrated on the theory and method point of view, and the significance of cost-effectiveness threshold to pharmacoeconomics was illustrated. RESULTS: There were 4 kinds of net benefits, and every kind of it was influenced by cost-effectiveness threshold. CONCLUSIONS: 4 kinds of net benefits are the function of cost-effectiveness threshold. Consequently, the sampling of cost-effectiveness threshold determines net benefits calculation directly.
展开▼
